Prof Soon Thye LIM
Dr Nicholas GRIGOROPOULOS
Dr Dachuan HUANG
Dr Jing TAN
Dr Tammy SONG
Dr Jing Quan LIM
Dr Miriam TAO
Dr Tiffany TANG
Dr Jason CHAN
Dr Nagavalli d/o SOMASUNDARAM
Dr Mohamed Farid BIN HARUNAL RASHID
Dr Yuh Shan LEE
Dr Nagarajan CHANDRAMOULI
Dr Chee Leong CHENG
Lay Poh KHOO
Suk Teng CHIN
The Lymphoma Genomic Translational Laboratory, led by Principal Investigator Dr. Choon Kiat ONG, is dedicated to gaining a better understanding of the pathogenesis and aetiology of lymphoma from a genomic perspective. Our laboratory is involved in the elucidation of the genomic and pathological facets of lymphoma, and subsequently translating significant findings into novel treatment approaches for patients through clinical trials.
To this end, our team takes on a systematic “bench-to-bedside” approach, whereby we first aim to understand the genomic basis of peripheral T-cell lymphoma (PTCL) and natural killer/T cell-lymphoma, and thereafter use these results to identify novel molecular targets for targeted therapeutics (Figure 1). To aid us in our pursuit to understand disease and treatment efficacy, we have established several patient-derived xenograft (PDX) models, with help from our clinical partners. Ultimately, our aim is to translate the discoveries from the laboratory into clinically implementable therapeutic strategies that would introduce new and more efficacious treatments for patients with lymphoma.
Over the years, our laboratory has secured research grants from various funding agencies, namely the National Medical Research Council (NMRC), the National Health Innovation Centre (NHIC), and the NCC Research Fund. We have also received industrial support for several projects from pharmaceutical companies, including Bayer Pharmaceuticals, ASLAN, Principia Biopharma, and SYNthesis Pte Ltd.
Recently, Dr. ONG, along with other collaborating scientists in the field of cancer research, was awarded the “AACR Team Science Award” by the American Association for Cancer Research (AACR), recognising the outstanding interdisciplinary team’s work in furthering the knowledge of Asian prevalent cancers and contributing to the progress of cancer detection, treatment and prevention. Dr. Ong is currently leading the whole-genome sequencing of T and natural killer-cell lymphoma at the International Cancer Genomic Consortium (ICGC). This initiative has proudly placed Singapore on the world map in the field of cancer genomic research.
Figure 1: The Jak-Stat signalling pathway is frequently activated in many cancers. Our discovery on identifying activating JAK3 mutation in NKTL leads to further effort on development and characterisation of JAK3 inhibitors in pre-clinical mouse model, and eventually towards clinical trials.
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Crescent, Singapore 169610 +65 6436 8000